Get access to our best features
Get access to our best features
Published 16 days ago

AbbVie Is 'Successfully Positioned To Absorb Humira Biosimilar Erosion': Analyst - AbbVie (NYSE:ABBV), Bristol-Myers Squibb (NYSE:BMY)

Summary by Benzinga
Cantor Fitzgerald initiates coverage on AbbVie with an Overweight rating and a $200 price target. AbbVie is set to manage Humira biosimilar erosion, drive growth with Skyrizi, Rinvoq, and emraclidine, and achieve a high single-digit CAGR from 2024 to 2029. Latest Ratings for ABBV DateFirmActionFromTo Feb 2022UBSDowngradesBuyNeutral Feb 2022MizuhoMaintainsBuy Feb 2022BarclaysMaintainsEqual-Weight View More Analyst Ratings for ABBV View the La…

0 Articles

All
Left
Center
Right
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe
Ground News Article Assistant
Not enough coverage to generate an Article Assistant.

Bias Distribution

  • 100% of the sources are Center
100% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)